2016
ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS
Sanai N, Li J, Boerner J, Dhruv H, Berens M, LoRusso P. ACTR-10. PHASE 0 TRIAL OF AZD1775 IN FIRST-RECURRENCE GLIOBLASTOMA PATIENTS. Neuro-Oncology 2016, 18: vi3-vi3. DOI: 10.1093/neuonc/now212.009.Peer-Reviewed Original ResearchPhase 0 trialsInterindividual variabilityGlioblastoma patientsPhase II studyApparent oral clearanceGlomerular filtration ratePhase I trialCL/F.CL/FSparse blood samplingElimination rate constantAbsorption rate constantPD endpointsAdult patientsII studyOral clearanceI trialSingle doseDrug exposureFiltration ratePreclinical modelsPreclinical studiesGlioma patientsPlasma ratioBlood sampling
2010
A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High‐Fat or Low‐Fat Meal in Patients With Advanced Solid Tumors
Heath E, Chiorean E, Sweeney C, Hodge J, Lager J, Forman K, Malburg L, Arumugham T, Dar M, Suttle A, Gainer S, LoRusso P. A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High‐Fat or Low‐Fat Meal in Patients With Advanced Solid Tumors. Clinical Pharmacology & Therapeutics 2010, 88: 818-823. PMID: 20980999, DOI: 10.1038/clpt.2010.199.Peer-Reviewed Original ResearchConceptsHigh-fat mealAdvanced solid tumorsGrowth factor receptorSolid tumorsMaximum observed plasma concentrationPlasma concentration-time curvePhase IAdministration of pazopanibOral angiogenesis inhibitorVascular endothelial growth factor receptorFactor receptorEndothelial growth factor receptorLow-fat mealObserved plasma concentrationConcentration-time curvePlatelet-derived growth factor receptorDaily pazopanibOral pazopanibSafety profileSystemic exposureSingle doseSingle dosesPlasma concentrationsPazopanibFasted condition
2006
A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs)
Eder J, Appleman L, Heath E, Malburg L, Zhu A, Pilat M, Shapiro G, Lorusso P. A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs). Journal Of Clinical Oncology 2006, 24: 3041-3041. DOI: 10.1200/jco.2006.24.18_suppl.3041.Peer-Reviewed Original ResearchConsecutive daily dosesAdvanced solid tumorsDaily dosesSolid tumorsSingle doseReceptor tyrosine kinasesSmall-molecule MET inhibitorTerminal half-life valuesGrade 2 hypertensionPapillary renal cell carcinomaSystemic drug exposurePeak plasma levelsRenal cell carcinomaTumor-associated vasculatureHepatocyte growth factor receptorGrowth factor receptorPharmacokinetic samplingPK samplingPartial responseRepeat dosingCell carcinomaMinor responsePlasma levelsDrug exposureMET inhibitors